By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Nanoparticles. According to news originating from Oporto, Portugal, by NewsRx correspondents, research stated, "This study intended to investigate the ability of solid lipid nanoparticles (SLN) to deliver camptothecin into the brain parenchyma after crossing the blood-brain barrier. For that purpose, camptothecin-loaded SLN with mean size below 200 nm, low polydispersity index (94%) were produced."
Our news journalists obtained a quote from the research from the University of Porto, "Synchrotron small and wide angle X-ray scattering (SAXS/WAXS) analysis indicates that SLN maintain their physical stability in contact with DMPC membrane, whereas SLN change the lamellar structure of DMPC into a cubic phase, which is associated with efficient release of the incorporated drugs. Cytotoxicity studies against glioma and macrophage human cell lines revealed that camptothecin-loaded SLN induced cell death with the lowest maximal inhibitory concentration (IC50) values, revealing higher antitumour activity of camptothecin-loaded SLN against gliomas. Furthermore, in vivo biodistribution studies of intravenous camptothecin-loaded SLN performed in rats proved the positive role of SLN on the brain targeting since significant higher brain accumulation of camptothecin was observed, compared to non-encapsulated drug. Pharmacokinetic studies further demonstrated lower deposition of camptothecin in peripheral organs, when encapsulated into SLN, with consequent decrease in potential side toxicological effects."
According to the news editors, the research concluded: "These results confirmed the potential of camptothecin-loaded SLN for antitumour brain treatments."
For more information on this research see: Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. European Journal of Pharmaceutics and Biopharmaceutics, 2013;85(3):488-502. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.elsevier.com/wps/product/cws_home/600120)
The news correspondents report that additional information may be obtained from S.M. Martins, University of Porto, Dept. of Quim, REQUIMTE, P-4100 Oporto, Portugal. Additional authors for this research include B. Sarmento, C. Nunes, M. Lucio, S. Reis and D.C. Ferreira (see also Nanoparticles).
Keywords for this news article include: Oporto, Europe, Portugal, Nanotechnology, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC